Merck Q3 Results - Q3 Top Pharma Company Earnings Reports

View Merck's Q3 Earnings Report

FiercePharma says: Merck posted better-than-expected profits, aided by a.) strong sales of its diabetes meds and HIV treatments; b.) a one-time $1.7 billion gain on the sale of its animal health business Merial; and c.) cost-cutting, particularly in marketing-and-administrative. Profits came in at $3.42 billion on a 2 percent growth in sales to $6.05 billion. Read more...

Highlights

• Third-Quarter 2009 Non-GAAP EPS Increases 13 Percent to $0.90, Excluding Certain Items; Reports Third-Quarter GAAP EPS of $1.61, Including Gain from Merial Sale
• Continued Growth of Key Products, JANUVIA, JANUMET, ISENTRESS and SINGULAIR, Drives Strong Results
• Merck Updates Full-Year 2009 Non-GAAP EPS Range to $3.20 to $3.30, Excluding Certain Items, and 2009 GAAP EPS Range to $3.69 to $3.89

Check out Merck's current earnings estimates from CNN Money

Merck's Website: http://www.merck.com

Related Articles:
Merck, Schering swing to 4Q profit
Merck's ivory tower is no more, CEO says
Generics expected to hit Merck, Pfizer earnings
Merck CEO: "Totally transparent" on doc dollars